α-硫辛酸改善了糖尿病性多神經病變患者的主觀感受
發布日期：2008-11-06 14:39 文章來源： Emerging Treatments and Technologies
分享到： 收藏夾 新浪微博 騰訊微博 開心網 豆瓣社區 人人網
關鍵詞： α-硫辛酸
糖尿病性多神經病變
點擊次數：
OBJECTIVE— Because ɑ-lipoic acid (ALA), a potent antioxidant, prevents or improves nerve conduction attributes, endoneurial blood flow, and nerve (Na(+) K(+) ATPase activity in experimental diabetes and in humans and may improve positive neuropathic sensory symptoms,in this report we further assess the safety and efficacy of ALA on the Total Symptom Score (TSS),a measure of positive neuropathic sensory symptoms.
RESEARCH DESIGN AND METHODS— Metabolically stable diabetic patients with symptomatic (stage 2) diabetic sensorimotor polyneuropathy (DSPN) were randomized to a parallel, double-blind study of ALA (600 mg) (n?= 60) or placebo (n?= 60) infused daily intravenously for 5 days/week for 14 treatments. The primary end point was change of the sum score of daily assessments of severity and duration of TSS. Secondary end points were sum scores of neuropathy signs (NIS), symptoms (NSC), attributes of nerve conduction, quantitative sensation tests (QSTs), and an autonomic test.
RESULTS— At randomization, the groups were not significantly different by the criteria of metabolic control or neuropathic end points. After 14 treatments, the TSS of the ALA group had improved from baseline by an average of 5.7 points and the placebo group by an average of 1.8 points (P=0.001). Statistically significant improvement from baseline of the ALA, as compared with the placebo group, was also found for each item of the TSS (lancinating and burning pain,asleep numbness and prickling), NIS, one attribute of nerve conduction, and global assessment of efficacy.
CONCLUSIONS— Intravenous racemic ALA, a potent antioxidant, rapidly and to a significant and meaningful degree, improved such positive neuropathic sensory symptoms as pain and several other neuropathic end points. This improvement of symptoms was attributed to improved nerve pathophysiology, not to increased nerve fiber degeneration. Because of its safety profile and its effect on positive neuropathic sensory symptoms and other neuropathic end points, this drug appears to be a useful ancillary treatment for the symptoms of diabetic polyneuropathy.
編輯: sd
以下網友留言只代表網友個人觀點，不代表網站觀點
|
